SEC Form S-8 filed by Rhythm Pharmaceuticals Inc.
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
As filed with the Securities and Exchange Commission on February 26, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Rhythm Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 46-2159271 | ||||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | ||||
222 Berkeley Street
12th Floor
Boston, MA 02116
(857) 264-4280
(Address of Principal Executive Offices) (Zip Code)
Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan
(Full title of the plan)
David P. Meeker, M.D.
Chief Executive Officer, President and Chairman of the Board
Rhythm Pharmaceuticals, Inc.
222 Berkeley Street
12th Floor
Boston, MA 02116
(857) 264-4280
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
With copies to:
Peter N. Handrinos, Esq.
Latham & Watkins LLP
John Hancock Tower
200 Clarendon Street
Boston, MA 02116
(617) 948-6060
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x | Accelerated filer ¨ | ||||
Non-accelerated filer ¨ | Smaller reporting company ¨ | ||||
Emerging growth company ¨ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ¨
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 2,688,212 shares of the Registrant’s common stock to be issued pursuant to the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan (the “Incentive Plan”). A Registration Statement of the Registrant on Form S-8 relating to the Incentive Plan is effective.
INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS ON FORM S-8
The contents of the Registration Statements on Form S-8 (File Nos. 333-220925, 333-223647, 333-229642, 333-236829, 333-253709, 333-263168, 333-270231, 333-277539, and 333-285411, including any amendments thereto, filed with the Securities and Exchange Commission, relating to the Incentive Plan, are incorporated herein by reference.
Item 8. Exhibits
Exhibit Number | Description | |||||||
| 4.1 | ||||||||
| 4.2 | ||||||||
| 4.3 | ||||||||
| 5.1* | ||||||||
| 23.1* | ||||||||
| 23.2* | ||||||||
| 24.1* | ||||||||
| 99.1 | ||||||||
| 99.2 | ||||||||
| 99.3 | ||||||||
| 107.1* | ||||||||
* Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on February 26, 2026.
| RHYTHM PHARMACEUTICALS, INC. | |||||
| By: | /s/ David P. Meeker, M.D. | ||||
| David P. Meeker, M.D. | |||||
| Chief Executive Officer, President and Chairman of the Board | |||||
POWER OF ATTORNEY
Each person whose signature appears below hereby constitutes and appoints David P. Meeker, M.D. and Hunter C. Smith, or each of them singly, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.
| Signature | Title | Date | ||||||||||||
| /s/ David P. Meeker, M.D. | Chief Executive Officer, President and Director | February 26, 2026 | ||||||||||||
| David P. Meeker, M.D. | (Principal Executive Officer) | |||||||||||||
| /s/ Hunter C. Smith | Chief Financial Officer | February 26, 2026 | ||||||||||||
| Hunter C. Smith | (Principal Financial Officer) | |||||||||||||
| /s/ Christopher P. German | Corporate Controller | February 26, 2026 | ||||||||||||
| Christopher P. German | (Principal Accounting Officer) | |||||||||||||
| /s/ Edward T. Mathers | Lead Director | February 26, 2026 | ||||||||||||
| Edward T. Mathers | ||||||||||||||
| /s/ Stuart Arbuckle | Director | February 26, 2026 | ||||||||||||
| Stuart Arbuckle | ||||||||||||||
| /s/ Jennifer L. Good | Director | February 26, 2026 | ||||||||||||
| Jennifer L. Good | ||||||||||||||
| /s/ Christophe R. Jean | Director | February 26, 2026 | ||||||||||||
| Christophe R. Jean | ||||||||||||||
| /s/ David W. J. McGirr | Director | February 26, 2026 | ||||||||||||
| David W. J. McGirr | ||||||||||||||
| /s/ Lynn A. Tetrault, J.D. | Director | February 26, 2026 | ||||||||||||
| Lynn A. Tetrault, J.D. | ||||||||||||||